Analysis, perspectives, and strategic frameworks on the forces shaping MedTech, healthcare AI, and global market access.
The FDA's action plan for artificial intelligence and machine learning in medical devices has matured significantly. Understanding the predetermined change control plan (PCCP) framework and its implications for AI device development is now a commercial imperative, not just a regulatory one.
The EU Medical Device Regulation has fundamentally reshaped the European MedTech market. From notified body capacity constraints to clinical evidence requirements, we examine what the data tells us about compliance timelines and market access implications.
The Hospital at Home movement has created a significant commercial opportunity for remote patient monitoring platforms. But capturing this opportunity requires a fundamental rethinking of business models, pricing architectures, and health system engagement strategies.
While the US and European surgical robotics markets mature, India and Southeast Asia represent the next major growth opportunity. We examine the market dynamics, hospital adoption patterns, and regulatory considerations that will shape the competitive landscape over the next five years.
The clinical evidence requirements for AI-based medical devices differ fundamentally from traditional device submissions. Understanding how to design studies that satisfy both regulatory requirements and clinical buyer expectations is a strategic advantage that few AI companies have fully exploited.
CMS coverage pathways for digital health technologies have expanded significantly, but the reimbursement landscape remains fragmented and complex. We map the key pathways — from CPT codes to Medicare Advantage coverage — and identify the strategic implications for digital health companies.
Southeast Asia's healthcare market is among the fastest-growing in the world, but it is not a single market. Understanding the regulatory, clinical, and commercial heterogeneity across Singapore, Malaysia, Thailand, Indonesia, and the Philippines is essential for any MedTech company considering regional expansion.
Artificial intelligence is transforming gastrointestinal diagnostics — from polyp detection to capsule endoscopy analysis. We examine the market landscape, competitive dynamics, and commercialization strategies for AI GI diagnostic companies navigating a rapidly evolving clinical and regulatory environment.
Join healthcare executives, MedTech founders, and investors who receive our monthly analysis on AI in healthcare, regulatory developments, and market access strategy.
No spam. Unsubscribe at any time.